The purpose of this study is to determine the effects of pregabalin on sleep problems in patients with seizures.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
17
Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28
Matching placebo capsules twice daily for 28 days
Pfizer Investigational Site
Heeze, Netherlands
Pfizer Investigational Site
The Hague, Netherlands
Change from baseline in polysomnographic (PSG) sleep efficiency in the efficacy evaluable population
Time frame: Endpoint
Change from baseline in total sleep time
Time frame: Endpoint
Change from baseline in sleep onset latency
Time frame: Endpoint
Change from baseline in wake after sleep onset
Time frame: Endpoint
Change from baseline in percent sleep spent in stages 3 and 4
Time frame: Endpoint
Change from baseline in percent sleep spent in REM stage
Time frame: Endpoint
Change from baseline in night sleep quality based on Groningen Sleep Questionnaire (GSQ)
Time frame: Endpoint
Change from baseline in 4-week sleep quality (Medical Outcomes Study [MOS] Sleep Scale)
Time frame: Endpoint
Adverse events and laboratory value changes
Time frame: Endpoint
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.